Catalyst
Key milestones include initial safety and efficacy results from both treatment arms, as well as any updates on patient enrollment and trial progression.
Humanexa recommends Monitor.
Date
June 25, 2026
Phase
N/A
Status
watch
Signal score
7.0
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.